PECAM1 and ovarian neoplasm: In the first-line setting, microvascular density – as evaluated by CD31 expression – and proliferative and mesenchymal gene expression subtypes were found to be associated with the efficacy of bevacizumab in the GOG218 and International Collaborative Ovarian Neoplasm Trial 7 (ICON7) trials, respectively [9, 10].